San Francisco, CA – Revolution Medicines, a clinical-stage oncology company, has unveiled compelling interim clinical data for its G12D-selective RAS(ON) inhibitor, zoldonrasib. The results from two distinct studies suggest significant potential for zoldonrasib as a combinatory agent in both first-line and second-line treatment settings for patients with KRAS G12D-mutated pancreatic cancer. This dual applicability positions the company for advancement into late-stage pipeline development and presents a formidable challenge to competitors in the burgeoning field of RAS-targeted therapies.
The company’s progress centers on its innovative approach to targeting the RAS pathway, a critical driver of many cancers, including a significant proportion of pancreatic ductal adenocarcinoma (PDAC). By specifically inhibiting the G12D mutation, Revolution Medicines aims to deliver a more precise and potentially more effective therapeutic strategy for a notoriously difficult-to-treat disease. The latest data, presented from ongoing trials, indicate that zoldonrasib, both as a monotherapy and in combination with existing chemotherapy regimens and other novel agents, is demonstrating promising efficacy and tolerability profiles.
Unveiling Frontline Potential: Zoldonrasib in Combination with Standard Chemotherapy
The ongoing Phase I/II RMC-GI-102 study (NCT06445062) has been evaluating zoldonrasib in combination with standard-of-care (SoC) chemotherapy in patients with frontline, RAS G12D-mutated metastatic pancreatic cancer. This pivotal study explores two distinct combination arms: zoldonrasib alongside modified FOLFIRINOX (mFFX) and zoldonrasib with gemcitabine plus nab-paclitaxel (GnP). The initial findings from this study are particularly noteworthy for their high objective response rates (ORR), a key indicator of treatment efficacy.
In the interim analysis, patients receiving the zoldonrasib-mFFX combination achieved an impressive ORR of 82%. This result has been characterized by Jefferies analysts as "impressive," underscoring its significance in a patient population with limited treatment options. The combination of zoldonrasib with gemcitabine plus nab-paclitaxel also demonstrated substantial efficacy, with an ORR of 61%. Beyond direct tumor shrinkage, the study reported robust disease control rates (DCR) when zoldonrasib was administered in tandem with chemotherapy. The mFFX regimen, in combination with zoldonrasib, achieved a DCR of 96%, while the GnP regimen showed a DCR of 90%. These high DCRs indicate that the combination therapies are effective at preventing tumor progression in a majority of patients.
Regarding tolerability, the zoldonrasib-chemotherapy regimens were generally well-tolerated, although a significant proportion of patients experienced treatment-emergent adverse events (TEAEs) rated Grade 3 or above. Specifically, 61% of patients treated with zoldonrasib-mFFX and 80% of those receiving zoldonrasib-GnP experienced such events. The most frequently reported TEAE across both arms was a decreased neutrophil count, affecting 37% of patients in the mFFX arm and 35% in the GnP arm. While these rates require careful monitoring and management, they are within expected ranges for these chemotherapy regimens, suggesting that the addition of zoldonrasib does not introduce an unmanageable toxicity burden.
These encouraging interim results from the RMC-GI-102 study are expected to strongly inform and support Revolution Medicines’ pivotal RASolute 305 study (NCT07621718). The RASolute 305 trial is designed as a head-to-head comparison, pitting zoldonrasib plus SoC chemotherapy against SoC plus placebo in frontline RAS G12D-mutated pancreatic ductal adenocarcinoma (PDAC). The success of the RMC-GI-102 study provides a solid foundation for the anticipated outcomes of RASolute 305, potentially paving the way for regulatory approval if the pivotal trial meets its endpoints.
Second-Line Promise: Zoldonrasib in Combination with Daraxonrasib
In addition to its promising role in the frontline setting, zoldonrasib has also demonstrated significant potential as a second-line treatment option when used in combination with Revolution Medicines’ pan-RAS inhibitor, daraxonrasib. This combination therapy is being explored in the Phase I RMC-9805-001 trial (NCT06040541), which enrolled patients with RAS G12D-mutated advanced solid tumors. The results from this trial are particularly exciting, as they suggest a new avenue for patients whose disease has progressed after initial treatments.
Daraxonrasib has garnered significant attention in the oncology community, with GlobalData analysts referring to it as a "turning point for pancreatic cancer" following its impressive performance in a pivotal study that nearly doubled overall survival (OS) in a patient cohort. The synergy observed between zoldonrasib and daraxonrasib in the RMC-9805-001 trial further amplifies the therapeutic potential of this dual-RAS targeting strategy.
In the RMC-9805-001 trial, the combination of zoldonrasib and daraxonrasib achieved an ORR of 50% and a remarkable DCR of 97% in patients with RAS G12D-mutated advanced solid tumors. These figures are particularly significant in the context of later-line therapies, where response rates often decrease due to the aggressive nature of relapsed or refractory disease.
Furthermore, the combination demonstrated encouraging survival metrics. In the second-line cohort, patients treated with zoldonrasib-daraxonrasib achieved a median progression-free survival (PFS) of 9.6 months. For patients in the third-line-plus setting, the median PFS was 7.6 months. While median overall survival (OS) was not yet estimable in the second-line group, indicating that a substantial portion of patients were still alive at the time of reporting, it reached 10.5 months in the third-line-plus setting. These survival data, particularly the promising PFS and the ongoing survival in the second-line group, highlight the durable and impactful nature of this combination therapy.
These compelling data from the RMC-9805-001 trial provide a strong rationale for Revolution Medicines’ plans to initiate the pivotal Phase III clinical trial, named RASolute 309. This trial will evaluate the efficacy of zoldonrasib-daraxonrasib against GnP in patients with frontline RAS G12D-mutated metastatic PDAC. The intention to explore this combination in the frontline setting, rather than solely in later lines of therapy, signifies the company’s confidence in its potential to become a first-line standard of care.
Strategic Implications and Competitive Landscape
The dual-pronged approach demonstrated by zoldonrasib, showing efficacy in both first-line and second-line settings, has significant strategic implications for Revolution Medicines. It offers a versatile platform that can potentially address a broad spectrum of patients with KRAS G12D-mutated pancreatic cancer throughout their treatment journey.
According to Jefferies analysts, Revolution Medicines has "set a very high bar" for other companies developing therapies targeting the RAS G12D mutation. This statement underscores the competitive advantage that the company may hold with its advanced pipeline. Several other pharmaceutical companies are actively pursuing similar targets. Verastem Oncology is exploring its candidate, VS-7375, in the Phase II, registration-directed TARGET-D 201 trial. Concurrently, Incyte is investigating its therapy, INCB161734, in a Phase I study. The success of Revolution Medicines’ zoldonrasib, particularly in demonstrating robust clinical outcomes, could set a benchmark for these emerging therapies and influence the trajectory of development in this specific area of oncology.
The company’s strategy of developing both selective inhibitors (like zoldonrasib) and pan-RAS inhibitors (like daraxonrasib) allows for a nuanced approach to targeting the complex RAS pathway. The ability to combine these agents, as demonstrated in the RMC-9805-001 trial, offers the potential for enhanced efficacy through multi-pronged attacks on the oncogenic signaling cascade. This approach is particularly valuable in pancreatic cancer, a disease known for its resistance to single-agent therapies.
The progression of zoldonrasib into late-stage pivotal trials, supported by these positive interim results, marks a significant milestone for Revolution Medicines. The company’s ability to generate such encouraging data in a challenging indication like pancreatic cancer speaks to the innovation and scientific rigor of its research and development efforts. As these trials advance, the oncology community will be closely watching to see if zoldonrasib can indeed fulfill its promise and become a new standard of care for patients battling this devastating disease. The potential impact on patient outcomes, combined with the company’s strong competitive positioning, makes Revolution Medicines a key player to monitor in the evolving landscape of cancer therapeutics.
About the Author
